AbbVie Inc. $ABBV is Railway Pension Investments Ltd’s 6th Largest Position

Railway Pension Investments Ltd cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 10.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 642,149 shares of the company’s stock after selling 78,200 shares during the quarter. AbbVie comprises 1.7% of Railway Pension Investments Ltd’s portfolio, making the stock its 6th largest holding. Railway Pension Investments Ltd’s holdings in AbbVie were worth $119,196,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Marshall & Sullivan Inc. WA purchased a new position in AbbVie during the 2nd quarter valued at $25,000. TD Capital Management LLC boosted its stake in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares in the last quarter. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the second quarter worth about $36,000. Finally, Bear Mountain Capital Inc. grew its holdings in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.4%

Shares of NYSE ABBV opened at $226.72 on Friday. The firm’s 50 day moving average price is $227.71 and its 200-day moving average price is $206.80. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market cap of $400.69 billion, a PE ratio of 107.96, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Bank of America increased their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. JPMorgan Chase & Co. upped their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Evercore ISI raised their target price on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Finally, DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research note on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.